SGLT2 Inhibitor Safe for Kidneys in Hospitalized COVID Patients
(MedPage Today) -- Taking sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) didn't hinder renal outcomes for patients hospitalized with COVID-19, according to a secondary analysis of the DARE-19 trial.
Among patients with...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | COVID-19 | Dapagliflozin | Forxiga | Heart | SGLT2 Inhibitors | Sodium | Urology & Nephrology